European Biosimilars Have ‘Room To Grow’ On Access And Understanding
Adrian Van Den Hoven, DG Of Medicines For Europe, Discusses Opportunities
In terms of broadening both access to treatment and stakeholder understanding, there remains plenty of room for growth for biosimilars in Europe, Medicines for Europe director general Adrian van den Hoven tells Generics Bulletin in an exclusive interview.
